· Venture Capital Tracker · investment-strategies · 3 min read
Onos Health’s $17M Series A: Behavioral Health AI for Health Plans
Costanoa led Onos Health’s $17M Series A with Flare Capital and CVS Health Ventures — Aetna already live. The product parses unstructured behavioral-health notes that legacy utilization tools miss.
Onos Health closed a $17 million Series A on August 26, 2026, led by Costanoa, with Flare Capital Partners and strategic CVS Health Ventures. Aetna is a named live customer; the company says 3 of the 6 largest U.S. health plans use the platform.
Unexpected truth: the AI story is not “chatbot for therapists.” It is payer infrastructure for unstructured behavioral-health documentation that utilization-management tools historically cannot read — Onos claims >70% of quality signals live in that unstructured layer.
Key facts
| Field | Detail |
|---|---|
| Company | Onos Health (San Francisco; founded 2024; CEO Akshay Agrawal, ex-Bain / Bain Capital) |
| Round | $17M Series A |
| Date | August 26, 2026 |
| Lead | Costanoa |
| Participants | Flare Capital Partners; CVS Health Ventures (strategic) |
| Prior | $6.3M seed (Oct 2025, Haystack + Pathlight co-lead per MedCity) → ~$23.5M total |
| Buyers | Health plans (Aetna named; 3/6 largest U.S. plans claimed) |
| Company-reported outcomes | 35% better clinical-standard adherence; 75% better review efficiency; >6% BH program cost cut in 12 months |
| Macro cited in PR | >23% of U.S. adults with annual MH condition; >$140B direct medical BH costs |
Who uses the product — and for what job
Users: health-plan clinical operations, quality, and behavioral-health teams — not individual therapists as the primary buyer.
Job: turn session notes + claims into measurable pathways so plans can partner with providers earlier, cut abrasive prior-auth theater, and manage total cost of care.
CVS Health Ventures’ Alyssa Reisner quote in the release frames the value as actionable insights from historically illegible data — a strategic investor speaking like a distribution partner.
Why now
- Behavioral health spend is huge and quality variance is poorly instrumented.
- Generative/document AI finally makes unstructured notes economically parseable at plan scale.
- Less than a year after seed, commercial logos (including Aetna) justify Series A acceleration — classic enterprise health timing.
Why this syndicate — portfolio fit
- Costanoa: Early enterprise/health software underwriter; partner Amy Cheetham’s quote positions Onos as foundational BH infrastructure, not a point chatbot.
- Flare Capital: Dedicated healthcare investor — category credibility for payer sales.
- CVS Health Ventures: Strategic capital when Aetna is already live — reduces go-to-market risk and aligns incentives for deeper deployment.
- Likely founder rationale: raise from a payer-fluent lead plus a strategic that is also a customer, not a general AI fund that cannot open plan doors.
No /fund/ pages yet for Costanoa, Flare, or CVS Ventures — we do not invent them.
Competitive map
| Player | Difference |
|---|---|
| Legacy UM / prior-auth vendors | Rules on structured claims; weak on notes |
| General clinical AI scribes | Provider workflow; Onos sells to plans |
| Flagler Health | Specialty clinic OS (MSK); different buyer |
| Consulting / chart-review shops | Human scale; Onos productizes the review |
Practical takeaway
- Founders (health AI): Name plan logos and which unstructured documents you parse — payers buy specificity.
- Investors: Separate company ROI claims from contract value; diligence the 6% cost-reduction methodology.
- Operators: Relevant if BH total cost of care is a 2026 board metric and notes are still a blind spot.
Sources
- https://www.prnewswire.com/news-releases/onos-health-raises-17-million-series-a-to-accelerate-adoption-of-its-behavioral-health-ai-platform-for-health-plans-302860046.html
- https://medcitynews.com/2026/08/onos-health-raises-17m-to-expand-ai-powered-behavioral-health-platform/
- https://bhbusiness.com/2026/08/26/onos-health-lands-17m-from-costanoa-flare-capital-cvs-ventures/
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.